Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences, the inventor of the flu vaccine Tamiflu, thought to be the best defense currently available against a global avian flu pandemic, has ended its dispute with Roche, the company that licensed the drug from Gilead in 1996.
Subscribe to our email newsletter
In June of this year, Gilead delivered a notice of termination to Roche of the companies’ 1996 agreement relating to Tamiflu and the companies subsequently entered into arbitration. However, the companies have now resolved the dispute between themselves.
Under the terms of the amended agreement, Gilead and Roche will establish joint committees to oversee manufacturing, commercial and pandemic planning for the product. Gilead will also have the option to co-promote Tamiflu in specialized areas in the US. Gilead will not co-promote Tamiflu in 2006 and has not yet determined whether it will exercise its option for co-promotion in 2007 or beyond.
“We have ended our dispute with Roche in an effort to work together, with the utmost diligence, to address this global public health need,” said Dr John Martin, president and CEO, Gilead Sciences.